NO20061460L - Legemiddel inneholdende (2R)-2-propyloktansyre som den aktive bestanddel - Google Patents

Legemiddel inneholdende (2R)-2-propyloktansyre som den aktive bestanddel

Info

Publication number
NO20061460L
NO20061460L NO20061460A NO20061460A NO20061460L NO 20061460 L NO20061460 L NO 20061460L NO 20061460 A NO20061460 A NO 20061460A NO 20061460 A NO20061460 A NO 20061460A NO 20061460 L NO20061460 L NO 20061460L
Authority
NO
Norway
Prior art keywords
drug containing
drug
propyloctanoic acid
active ingredient
salt
Prior art date
Application number
NO20061460A
Other languages
English (en)
Norwegian (no)
Inventor
Masao Sudoh
Seiichi Tanikawa
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of NO20061460L publication Critical patent/NO20061460L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Details Of Rigid Or Semi-Rigid Containers (AREA)
NO20061460A 2003-10-03 2006-03-31 Legemiddel inneholdende (2R)-2-propyloktansyre som den aktive bestanddel NO20061460L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003345124 2003-10-03
PCT/JP2004/014892 WO2005032536A1 (fr) 2003-10-03 2004-10-01 Medicament contenant un acide (2r)-2-propyloctanoique comme principe actif

Publications (1)

Publication Number Publication Date
NO20061460L true NO20061460L (no) 2006-07-03

Family

ID=34419441

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061460A NO20061460L (no) 2003-10-03 2006-03-31 Legemiddel inneholdende (2R)-2-propyloktansyre som den aktive bestanddel

Country Status (21)

Country Link
US (1) US8053599B2 (fr)
EP (1) EP1669065B1 (fr)
JP (1) JP4715515B2 (fr)
KR (1) KR101144553B1 (fr)
CN (1) CN1889942B (fr)
AU (1) AU2004277826B2 (fr)
BR (1) BRPI0415001A (fr)
CA (1) CA2540670A1 (fr)
EC (1) ECSP066477A (fr)
ES (1) ES2390055T3 (fr)
IL (1) IL174655A0 (fr)
IS (1) IS8430A (fr)
MA (1) MA28142A1 (fr)
MX (1) MXPA06003533A (fr)
NO (1) NO20061460L (fr)
NZ (1) NZ546231A (fr)
RU (1) RU2388467C2 (fr)
SG (1) SG146687A1 (fr)
TW (1) TW200519080A (fr)
WO (1) WO2005032536A1 (fr)
ZA (1) ZA200602690B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200613009A (en) * 2004-06-11 2006-05-01 Ono Pharmaceutical Co Capsule having chewing stability
TWI462745B (zh) * 2005-04-28 2014-12-01 Takeda Pharmaceutical 安定的乳化組成物
JP5541845B2 (ja) * 2008-03-28 2014-07-09 Ｊｃｒファーマ株式会社 アトピー性皮膚炎治療剤
CA2742659C (fr) * 2008-11-04 2016-09-27 Aska Pharmaceutical Co., Ltd. Composition aqueuse contenant de l'hormone folliculostimulante
KR20110083604A (ko) 2008-11-20 2011-07-20 테이코쿠 팔마 유에스에이, 인코포레이티드 피라졸론 유도체 제제
JP5759804B2 (ja) * 2011-06-27 2015-08-05 富士フイルム株式会社 容器詰製剤
JP2018052861A (ja) * 2016-09-29 2018-04-05 ノーベルファーマ株式会社 ホスフェニトインナトリウム注射剤
WO2020128928A1 (fr) * 2018-12-19 2020-06-25 Jafari Javid Mihan Formulation pour le traitement de troubles neurodégénératifs ainsi que de démyélinisation et neuropathiques et sa méthode de préparation
CN110441421B (zh) * 2019-08-02 2022-09-09 聊城高新生物技术有限公司 一种高效液相色谱法测定恩他卡朋片溶出度的方法
CN112180095B (zh) * 2020-06-04 2023-10-13 三诺生物传感股份有限公司 一种心脑血管和糖尿病相关四高指标复合质控品及其制备方法
IT202000015895A1 (it) * 2020-07-27 2022-01-27 Univ Cattolica Del Sacro Cuore L’impiego di acido arundico nella terapia della sclerosi multipla
CA3218713A1 (fr) * 2021-05-26 2022-12-01 Daewoong Pharmaceutical Co., Ltd. Contenant de medicaments contenant une composition pharmaceutique liquide de 1-(5-(2,4-difluorophenyl))-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
CN113341019A (zh) * 2021-06-09 2021-09-03 江西省药品检验检测研究院 一种乳酸左氧氟沙星氯化钠注射液中依地酸盐的分析方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0632008T3 (da) * 1993-06-01 1998-09-23 Ono Pharmaceutical Co Pentansyrederivater
JPH0782146A (ja) * 1993-07-23 1995-03-28 Sagami Chem Res Center 抗痴呆薬
JPH07285911A (ja) * 1994-04-20 1995-10-31 New Japan Chem Co Ltd 脂肪族モノカルボン酸組成物
JPH0853351A (ja) * 1994-08-11 1996-02-27 Sagami Chem Res Center 酵素阻害剤、血管新生抑制剤、および癌転移抑制剤
JP3032447B2 (ja) * 1995-04-24 2000-04-17 小野薬品工業株式会社 光学活性な２−プロピルオクタン酸の製造方法
JP3084345B2 (ja) 1995-04-26 2000-09-04 小野薬品工業株式会社 光学活性な２−プロピルオクタン酸の製造方法
JPH10298072A (ja) 1997-04-17 1998-11-10 Panacea Biotec Ltd 非ステロイド性抗炎症剤の遷移金属錯体
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
TWI268921B (en) * 1999-02-18 2006-12-21 Ono Pharmaceutical Co A process for preparing (2R)-2-propyloctanoic acid
US6552082B2 (en) * 2000-06-29 2003-04-22 Ono Pharmaceutical Co., Ltd. Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof
KR100759771B1 (ko) * 2000-07-18 2007-10-04 오노 야꾸힝 고교 가부시키가이샤 성상세포 기능 개선제를 유효 성분으로 함유하는 파킨슨병치료제
JP4706950B2 (ja) 2000-07-18 2011-06-22 小野薬品工業株式会社 アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤
CA2453478A1 (fr) * 2001-07-18 2003-01-30 Ono Pharmaceutical Co., Ltd. Agent pour le traitement des maladies ischemiques cerebrales

Also Published As

Publication number Publication date
US8053599B2 (en) 2011-11-08
EP1669065B1 (fr) 2012-07-18
RU2388467C2 (ru) 2010-05-10
MA28142A1 (fr) 2006-09-01
EP1669065A4 (fr) 2009-12-16
CN1889942A (zh) 2007-01-03
KR101144553B1 (ko) 2012-05-11
CN1889942B (zh) 2010-12-15
WO2005032536A1 (fr) 2005-04-14
ES2390055T3 (es) 2012-11-06
AU2004277826A1 (en) 2005-04-14
IS8430A (is) 2006-04-26
JPWO2005032536A1 (ja) 2006-12-14
CA2540670A1 (fr) 2005-04-14
SG146687A1 (en) 2008-10-30
AU2004277826B2 (en) 2010-05-27
KR20060099525A (ko) 2006-09-19
JP4715515B2 (ja) 2011-07-06
ZA200602690B (en) 2007-07-25
NZ546231A (en) 2009-09-25
TW200519080A (en) 2005-06-16
BRPI0415001A (pt) 2006-11-07
RU2006114835A (ru) 2007-11-20
IL174655A0 (en) 2006-08-20
MXPA06003533A (es) 2006-06-08
ECSP066477A (es) 2007-03-29
US20070105956A1 (en) 2007-05-10
EP1669065A1 (fr) 2006-06-14

Similar Documents

Publication Publication Date Title
NO20061460L (no) Legemiddel inneholdende (2R)-2-propyloktansyre som den aktive bestanddel
RU2011153403A (ru) Стабилизированная композиция, содержащая по меньшей мере одно адренергическое соединение
DE602005014393D1 (de) Stabile pharmazeutische zusammensetzungen aus antitumoralen platin-(ii)-mitteln
AU2011101749A4 (en) Injection of enrofloxacin and producing method thereof
NO20061458L (no) Infusjonspreparat inneholdende (2R)-2-propyloktansyre som den aktive bestanddel
RU2016147362A (ru) Препараты жидкого концетрата циклофосфамида
RU2016138577A (ru) Жидкая фармцевтическая композиция
RU2020114880A (ru) Стабилизированные инъекционные фармацевтические композиции l- эпинефрина
CN101578103A (zh) 抗生素的注射剂及其给予液
EA201992685A1 (ru) Раствор леводопы для инфузий
PE20090476A1 (es) Soluciones farmaceuticas
CN103251554A (zh) 一种稳定的依达拉奉注射液及其制备方法
RU2013148799A (ru) Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта
RU2010134748A (ru) Препарат для коррекции обменных процессов и повышения естественной резистентности организма животных
CN103637980A (zh) 一种盐酸异丙嗪注射液的制备方法
UA84578C2 (ru) Лекарственное средство, содержащее (2r)-2-пропилоктановую кислоту в качестве активного ингредиента
AU2004263036A1 (en) Glycyrrhizin high-concentration preparation
RU2014148062A (ru) Инъекционная фармацевтическая композиция декскетопрофена и трамадола
EA201791409A1 (ru) Препараты для инъекций парацетамола
US20060078541A1 (en) Method and formula for stem cells' stimulation, targeting release, trafficking and homing
Dominguez-Gonzalez et al. Correlates of receiving injection assistance among people who inject drugs (PWID) in Los Angeles and San Francisco, CA, 2011-13
RU2472507C1 (ru) Водный состав на основе моксифлоксацина для парентерального введения
AR049015A1 (es) Composicion farmaceutica que comprende acido (2r)-2-propiloctanoico como un ingrediente activo
CN103877016A (zh) 一种盐酸纳洛酮注射液药物组合物及其制备方法
RU2204389C1 (ru) Цестодоцидная комплексная лекарственная композиция

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application